Literature DB >> 11553916

Degradation of maternal cdc25c during the maternal to zygotic transition is dependent upon embryonic transcription.

J E Anderson1, R L Matteri, L R Abeydeera, B N Day, R S Prather.   

Abstract

To gain a better understanding of the molecular differences that may contribute to cleavage arrest and the poorer development associated with laboratory produced embryos, a series of experiments were conducted to quantitate the message levels of the cell cycle controller cdc25c, over the maternal to zygotic transition (MZT) in 4-cell in vivo- and in vitro-derived porcine embryos. The experiments were designed to measure both maternal and embryonic derived cdc25c transcripts by quantitative reverse transcription-competitive polymerase chain reaction (RT-cPCR), determine the point of the transition to zygotic genome activation, and study the interaction between initial embryonic transcription and maternal cdc25c degradation. Analysis of in vivo- and in vitro-derived embryos revealed no difference in cdc25c message level for any of the times P4CC (P > 0.05). Comparison of control embryos from 5- to 33-hr P4CC revealed a reduction in transcript quantities in the 10-hr P4CC group that was maintained at later time points (P < 0.05). Embryos cultured in the RNA polymerase inhibitor, alpha-amanitin, from cleavage to 5-, 10-, 18-, 25-, or 33-hr P4CC displayed no difference in cdc25c levels when compared to controls at similar time points (P > 0.05). However, if embryos were first exposed to alpha-amanitin after 18-hr P4CC with this treatment continuing to 33 hr, the levels of cdc25c transcript were reduced (P < 0.04) when compared to those embryos that were first exposed to the inhibitor at either 5- or 10-hr P4CC. This finding and the comparison of these same embryos to the 0-33-hr alpha-amanitin and control groups allowed us to conclude that cdc25c transcription began between 10- and 18-hr P4CC, with the degradation of maternal cdc25c message dependent on transcriptional initiation. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553916     DOI: 10.1002/mrd.1075

Source DB:  PubMed          Journal:  Mol Reprod Dev        ISSN: 1040-452X            Impact factor:   2.609


  7 in total

Review 1.  Regulation of gene expression in mouse embryos and its embryonic cells through RNAi.

Authors:  Karin Lykke-Andersen
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

Review 2.  Transcriptional, post-transcriptional and epigenetic control of porcine oocyte maturation and embryogenesis.

Authors:  R S Prather; J W Ross; S Clay Isom; J A Green
Journal:  Soc Reprod Fertil Suppl       Date:  2009

Review 3.  In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets.

Authors:  Hiroaki Kiyokawa; Dipankar Ray
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

4.  Transgenic pig carrying green fluorescent proteasomes.

Authors:  Edward L Miles; Chad O'Gorman; Jianguo Zhao; Melissa Samuel; Eric Walters; Young-Joo Yi; Miriam Sutovsky; Randall S Prather; Kevin D Wells; Peter Sutovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-02       Impact factor: 11.205

Review 5.  A Comparative Analysis of Oocyte Development in Mammals.

Authors:  Rozenn Dalbies-Tran; Véronique Cadoret; Alice Desmarchais; Sébastien Elis; Virginie Maillard; Philippe Monget; Danielle Monniaux; Karine Reynaud; Marie Saint-Dizier; Svetlana Uzbekova
Journal:  Cells       Date:  2020-04-17       Impact factor: 6.600

6.  Maternal Argonaute 2 is essential for early mouse development at the maternal-zygotic transition.

Authors:  Karin Lykke-Andersen; Michael J Gilchrist; Joanna B Grabarek; Partha Das; Eric Miska; Magdalena Zernicka-Goetz
Journal:  Mol Biol Cell       Date:  2008-08-13       Impact factor: 4.138

7.  Validation of reference genes for quantitative RT-PCR studies in porcine oocytes and preimplantation embryos.

Authors:  Ewart W Kuijk; Leonie du Puy; Helena T A van Tol; Henk P Haagsman; Ben Colenbrander; Bernard A J Roelen
Journal:  BMC Dev Biol       Date:  2007-05-31       Impact factor: 1.978

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.